ic9/car.19/il15-transduced cb-nk cells
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2017 (NCT03056339)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ic9/car.19/il15-transduced cb-nk cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03056339 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2017 | Bellicum Pharmaceuticals, University of Texas at Houston |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bellicum Pharmaceuticals | For profit | 1 | 0 | 1 | 2017 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2017 |
2 organizations
Page 1 / 1